Phosphocitrate blocks calcification-induced articular joint degeneration in a guinea pig model

Arthritis and Rheumatism

Volumn 54, Issue 8, 2006, Pages 2452-2461

  Cheung, Herman S ^a,b   Sallis, John D ^a   Demadis, Konstantino D ^c   Wierzbicki, Andrzej ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF CRETE   (Greece)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SODIUM PHOSPHOCITRATE; CITRIC ACID; PHOSPHOCITRIC ACID; UNCLASSIFIED DRUG;

AGE; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIFICATION; CARTILAGE DEGENERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; EVALUATION; GUINEA PIG; JOINT DEGENERATION; KNEE MENISCUS; MALE; MENISCECTOMY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RABBIT;

ANIMALS; CALCINOSIS; CALCIUM; CARTILAGE, ARTICULAR; CITRATES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GUINEA PIGS; JOINTS; MALE; MENISCI, TIBIAL; OSTEOARTHRITIS, KNEE; RABBITS; STIFLE;

EID: 33746960228     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22017     Document Type: Article

References (49)

1. Rosenthal AK, Ryan LM. CPPD crystal deposition disease. In: Koopman WJ, editor. Arthritis and allied conditions. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 2348-54.
2. Halverson PB. BCP crystal deposition disease and calcinosis. In: Koopman WJ, editor. Arthritis and allied conditions. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2372.
3. Schumacher HR. Crystals & osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. New York: Oxford University Press; 1998. p. 137-44.
4. Cheung HS. Role of calcium-containing crystals in osteoarthritis. Front Biosci 2005;10:1336-40.
5. Kapadia RD, Badger AM, Levin JM, Swift B, Bhattacharya A, Dodds RA, et al. Meniscal ossification in spontaneous osteoarthritis in the guinea-pig. Osteoarthritis Cartilage 2000;8:374-7.
6. Cheung HS. Biologic effects of calcium-containing crystals. Curr Opin Rheumatol 2005;17:336-40.
7. Cheung HS. Phosphocitrate as a potential therapeutic strategy for cystal deposition disease. Curr Rheumatol Rep 2001;3:24-28.
8. Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis 1983;42 Suppl:106-7.
9. Xu Y, Cruz TF, Pritzker KPH. Alkaline phosphate dissolves CPPD crystals. J Rheumatol 1991;18:1606-10.
10. Bennett RM, Lehr JR, McCarty DJ. Crystal shedding and acute pseudogout: an hypothesis based on a therapeutic failure. Arthritis Rheum 1976;19:93-7.
11. Tew WP, Malis CD, Howard JE, Lehninger AL. Phosphocitrate inhibits mitochondrial and cytosolic accumulation of calcium in kidney cells in vivo. Proc Natl Acad Sci U S A 1981;78:5528-32.
12. Moro L, Stagni N, Luxich E, Sallis JD, DeBernard B. Evidence in vitro for an enzymatic synthesis of phosphocitrate. Biochem Biophys Res Commun 1990;170:251-8.
13. Cheung HS, Sallis JD, Mitchell P, Struve JA. Inhibition of basic calcium phosphate crystal-induced mitogenesis by phospocitrate. Biochem Biophys Res Commun 1990;171:20-5.
14. Cheung HS, Kurup IV, Sallis JD, Ryan LM. Inhibibition of CPPD crystal formation in articular cartilage vesicles and cartilage by phosphocitrate. J Biol Chem 1996;271:28082-5.
15. Nair D, Misra RP, Sallis JD, Cheung HS. Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway. J Biol Chem 1997;272:18920-5.
16. Reuben PM, Wenger L, Cruz M, Cheung HS. Induction of metalloproteinase-8 in human fibroblasts by basic calcium phosphate crystals: effect of phosphocitrate. Connect Tissue Res 2001;42:1-12.
17. Cheung HS, Sallis JD, Struve JA. Specific inhibition of BCP and CPPD crystal-induced collagenase and stromelysin snthesis by phosphocitrate. Biochem Biophys Acta 1996;1315:105-11.
18. Cheung HS. Mechanism of destructive arthropathy and its prevention with phosphocitrate. Rev Bras Rheum 1994;34 Suppl:S117-9.
19. Dalal P, Zannotti A, Wierzbicki A, Madura JD, Cheung HS. Molecular dynamics simulation studies of phosphocitrate effect on crystal-induced membranolysis. Biophys J 2005;89:1-7.
20. Wierzbicki A, Cheung HS. Molecular modeling of inhibition of crystals of CPPD by phosphocitrate. J Mol Struct 1998;454:287-91.
21. Wierzbicki A, Cheung HS. Molecular modeling of inhibition of hydroxyapatite crystal by phosphocitrate. J Mol Struct 2000;529:73-82.
22. Wierzbicki A, Dalal P, Madura JD, Cheung HS. Molecular dynamics simulation of crystal induced membronolysis. J Phys Chem B Mater Surf Interfaces Biophys 2003;107:12346-51.
23. Tew WP, Mahle CD, Benavides J, Howard JE, Lehninger AL. Synthesis and characterization of phosphocitric acid, a potent inhibitor of hydroxylapatite crystal growth. Biochemistry 1980;19:1983-8.
24. Shankar R, Crowden S, Sallis JD. Phosphocitrate and its analogue N-sulpho-2-amino tricarballylate inhibit aortic calcification. Atherosclerosis 1984;50:191-8.
25. Sallis JD, Cheung HS. Inhibitors of articular calcium crystal formation. Curr Opin Rheumatol 2003;15:321-5.
26. Reuben P, Brogley M, Sun Y, Cheung HS. Molecular mechanism of the induction of metallopriteinases 1 and 3 in human fibroblasts by basic calcium phosphate crystals: role of calcium-dependent protein kinase C-a. J Biol Chem 2002;277:15190-8.
27. 2 production in human fibroblasts: role of cyclooxygenase 1, cyclooxygenase 2, and interleukin-1β. Arthritis Rheum 2004;50:1642-9.
28. Cheung HS, Ryan LM. Phosphocitrate blocks nitric oxide-induced calcification of cartilage and chondrocyte-derived apoptotic bodies. Osteoarthritis Cartilage 1999;7:409-12.
29. Demadis KD, Sallis JD, Raptis RG, Baran P. A crystallographically characterized nine-coordinated calcium-phosphocitrate complex as calcification inhibitor in vivo. J Am Chem Soc 2001;123:10129-30.
30. Bendele AM, White SL, Hulman JF. Osteoarthritis in guinea pigs: histopathologic and scanning electron microscopic features. Lab Anim Sci 1989;39:115-21.
31. Bendele AM, Hulman JF. Spontaneous cartilage degneration in guinea pigs. Arthritis Rheum 1988;31:561-5.
32. Watson PJ, Hall LD. Malcolm A, Tyler JA. Degenerative joint disease in the guinea pig: use of magnetic resonance imaging to monitor progression of bone pathology. Arthritis Rheum 1996;39:1327-37.
33. Huebner JL, Otterness IG, Freund EM, Caterson B, Krause VB. Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis. Arthritis Rheum 1998;41:877-90.
34. McCarty DJ, Hogan JM, Gatter RA. Studies of pathological calification in human cartilage. I. Prevalence and types of crystal deposits in the menisci of two hundred and fifteen cadavera. J Bone Joint Surg 1966;48A:308-25.
35. Meachim G. Light microscopy of Indian ink preparation of fibrillated cartilage. Ann Rheum Dis 1972;31:457-64.
36. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg 1971;53:523-37.
37. Doyle DV, Dunn CJ, Willoughby DA. An animal calcergy model. J Pathol 1979;128:63-9.
38. Williams G, Sallis JD. Structural factors influencing the ability of compounds to inhibit HA formation. Calcif Tissue Int 1982;34:169-77.
39. Moskowitz RW, Davis W, Sammarco J, Martens M, Baker J, Mayor M, et al. Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit. Arthritis Rheum 1973;16:397-405.
40. Moskowitz RW, Goldberg VM. Studies of osteophyte pathogenesis in experimentally induced osteoarthritis. J Rheumatol 1987;14:311-20.
41. 32P-labelled phosphocitrate and analytical systems for its identification. Anal Biochem 1980;102:365-373.
42. Meehan JD, Sallis JD. Kidney selective prodrugs of phosphocitrate: synthesis and in vivo hydrolysis of -glutamyl derivatives of phosphocitrate and their in vivo influence on nephrocalcinosis. Pharm Sci 1995;1:289-94.
43. Krug HE, Mahowald ML, Halverson PB, Sallis JD, Cheung HS. Phosphocitrate prevents disease progression in murine progressive ankylosis. Arthritis Rheum 1993;36:1603-11.
44. Moskowitz RW. Experimental models of osteoarthritis. In: Moskowitz RW, Howell DS, Goldberg VM, Mankin HJ, editors. Osteoarthritis: diagnosis and medical/surgical management. Philadelphia: WB Saunders; 1992. p. 213-32.
45. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, editor. Arthritis & allied conditions. Baltimore: Williams & Wilkins; 1997. p. 1969-84.
46. Loening AM, James IE, Levenston ME, Nuttall ME, Hung HK, Gowen M, et al. Injurious compression of bovine articular cartilage induces chondrocytes apoptosis before detectable mechanical damage. J Orthop Res 1999;24:42-5.
47. Sallis JD, Wierzbicki A, Cheung HS. Calcium pyrophosphate crystal forms and the influence of phosphocitrate. In: Amzad Z, editor. Advance in crystal growth inhibition technologies. Philadelphia: Plenum; 2001. p. 57-70.
48. Shankar R, Tuyethong N, Sallis JD. Atherogenesis: mitigation of monocyte adhesion to arterial endothelium in hyperlipidemic rats by phosphocitrate, a phosphorylated polycarboxylic acid. Atherosclerosis 1986;52:191-8.
49. Kraus VB, Huebner JL, Stabler T, Flahiff CM, Setton LA, Fink C, et al. Ascorbic acid increases the severity of spontaneous knee osteoarthritis in a guinea pig model. Arthritis Rheum 2004;50:1822-31.